Source: Gerd Altmann, no changes made.
Alnylam, a global leader in RNAi therapeutics, has selected Paradigm4 as its partner to make the most of the company’s investment in UK Biobank data. Paradigm4’s REVEAL™ and PheGe™ software will help Alnylam to identify patient cohorts based on medical records combined with advanced phenotype technologies such as imaging and wearables to uncover genetic and metabolic drivers of disease.
The UK Biobank is a ground-breaking international health resource with more than 1.5 petabytes of data planned for collection and analysis: medical records, genomic data, imaging, and measurements donated by 500,000 UK citizens.
Founded in 2002, headquartered in Cambridge, Massachusetts, USA, Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS) diseases.
Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Alnylam achieved an RNAi therapeutic approval by the FDA this year for patisiran/ONPATTRO™ in adults with hereditary transthyretin mediated amyloidosis (hATTR).
Paradigm4 Inc., founded in 2009 by renowned database researcher, Turing Award laureate MIT Professor, Michael Stonebraker, headquartered in Waltham, Massachusetts, USA, is a scientific information solutions provider.
Leading Life Sciences, IoT, instrument, and research institutes use Paradigm4’s REVEAL™ discovery engine for collaborative, reproducible research. The company advances scientific and engineering insights by enabling scientists and data scientists to take full advantage of the scale, resolution, and diversity of public and proprietary scientific data to accelerate their research.
Paradigm4’s recently launched REVEAL™ Translational Informatics Platform with its PheGe™ Browser enables bioinformaticians and scientists to readily work with the scale and diversity of public and proprietary multi-omics, behavioral, clinical, health outcomes, and environmental data generated today.
Built on Paradigm4’s scientific data computational engine for complex data analysis and machine learning, REVEAL™ accelerates integrative, multi-modal, longitudinal, population-scale data science exploration and discovery.
“The absolute scale and diversity of the data in the UK Biobank will drive transformational GWAS/PheWAS research,” … “Our aggressive timelines provide Alnylam—along with our other top biopharma customers—with best-in-class performance and services to rapidly mine this valuable data set.” – Paradigm4’s CEO Marilyn Matz
“The UK Biobank dataset redefines our view of Real-World Evidence to support active clinical development projects where new insights into cohort selection for recruiting or stratifying patients are very valuable.” … “The UK Biobank data in REVEAL™ is a unique resource for in-silico trial simulations with its ease of data selection and support for optimizing machine learning parameters. Enabling customers with a truly private analytical environment offers a distinct advantage in a competitive market like drug development.” – Zachary Pitluk, Ph.D., V.P. of Life Sciences, Paradigm4
Sources:
